A New Therapeutic for Liposarcoma
The newly approved therapeutic increased overall survival for patients whose disease had progressed despite treatment with a certain type...
Progress Against Cancer
The newly approved therapeutic increased overall survival for patients whose disease had progressed despite treatment with a certain type...
The U.S. Food and Drug Administration approval provides a new treatment option for patients whose cancer is not responding...
The U.S. Food and Drug Administration approval is intended for patients who have not previously been treated for advanced...
The U.S. Food and Drug Administration approval provides a new option for patients with the most common type of...
Ixazomib is the first medication of its kind to be given to patients orally The U.S. Food and Drug...
Elotuzumab became the third new treatment for multiple myeloma approved by the U.S. Food and Drug Administration in a...
Daratumumab is the first monoclonal antibody approved by the U.S. Food and Drug Administration for patients with multiple myeloma...
The U.S. Food and Drug Administration approval provides a new option for patients whose disease is driven by mutations...
The U.S. Food and Drug Administration approval provides a new option for patients with the most deadly form of...
The U.S. Food and Drug Administration approval provides a new option for patients with liposarcoma and leiomyosarcoma that is...